Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Rheumatology

Standard of Care and Treatment Pathways

At a Glance

Antisynthetase Syndrome (ASyS) is typically treated with a combination of medications to calm the immune system and protect the lungs and muscles. Standard care involves starting with fast-acting corticosteroids alongside steroid-sparing agents like mycophenolate mofetil or azathioprine.

Because Antisynthetase Syndrome (ASyS) involves an overactive immune system attacking your own tissues, the goal of treatment is to “calm” the immune system enough to stop the damage while keeping you safe from infections [1][2]. Standard care is rarely just one medication; it is almost always a combination of therapies tailored to how the disease affects your lungs, muscles, and joints [3][4].

First-Line Therapy: The Foundation

For most patients, treatment begins with a “two-pronged” approach to hit the disease hard and fast.

  1. Corticosteroids (e.g., Prednisone): These are the “emergency responders.” They work quickly to reduce inflammation throughout the body [1][5]. While highly effective, they have significant side effects when used long-term—including insomnia, weight gain, bone density loss, blood sugar spikes, and mood changes—so doctors aim to “taper” (lower) the dose as soon as it is safe [6].
  2. Steroid-Sparing Agents: To reduce the need for high-dose steroids, doctors add a second immunosuppressant. The most common choices are Mycophenolate Mofetil (MMF) or Azathioprine [2][7]. These medications take longer to work (often weeks or months) but are safer for long-term use and help keep the disease in remission. It is important to remember that these medications lower your immune defenses, meaning your risk of infection increases. You will need to stay vigilant about hygiene and keep up to date on recommended non-live vaccines [2][8].

Escalating Care: Second-Line and Biologics

If the first-line combination is not enough to stop the disease, or if your symptoms are severe from the start, your care team may move to more advanced options:

  • Rituximab: This is a biologic (a lab-made protein) given by infusion that specifically targets the B-cells in your immune system that produce the harmful autoantibodies [2][9]. It is often used as a “rescue” therapy or even as a first-line option for patients with anti-Jo-1 antibodies or significant lung involvement [10][11].
  • Calcneurin Inhibitors (e.g., Tacrolimus): These are specialized immunosuppressants that can be particularly effective for the lung inflammation seen in ASyS [6].

Treatment for Rapidly Progressive ILD (RP-ILD)

In some cases, lung inflammation moves very quickly—over days or weeks rather than months [12][13]. This is a medical emergency that requires a specialized algorithm:

  • Triple Therapy: Doctors may use high-dose “pulse” steroids, MMF, and Rituximab all at once [2][14].
  • Advanced Salvage: If triple therapy fails, specialists may turn to JAK inhibitors (like tofacitinib), cyclophosphamide, or even plasmapheresis (a process that “washes” the autoantibodies out of your blood) [15][14][16].

Emerging Options

Research into ASyS is moving fast. New treatments being studied in clinical trials or used “off-label” for difficult cases include:

  • JAK Inhibitors: Oral medications that block specific inflammation pathways [17].
  • IL-6 Inhibitors: Biologics that target a specific inflammatory protein called Interleukin-6 [18].
  • T-Cell Engagers: Highly advanced investigational therapies that “retrain” your T-cells to find and destroy the cells making harmful antibodies [19].

Management Red Flags

Because ASyS is rare, you may encounter doctors who have limited experience with it. Be cautious if your treatment plan includes the following “red flags”:

  • “Steroid-Only” Treatment: Except for the very mildest cases, relying only on prednisone without adding a second immunosuppressant is generally considered insufficient for ASyS [1][2].
  • Wait-and-See for Lungs: If you have lung involvement (ILD), current guidelines recommend aggressive early treatment rather than waiting for symptoms to get worse [3][20].
  • No Specialist Coordination: If your rheumatologist and pulmonologist are not communicating, your care may be fragmented [4][21]. Coordinating these two specialties is the standard of care for this condition [4].

Common questions in this guide

Why do doctors prescribe both steroids and other medications for ASyS?
Treatment usually begins with a combination approach. Corticosteroids work quickly to reduce inflammation, while steroid-sparing agents like mycophenolate mofetil are added to maintain remission and reduce the need for high-dose steroids over time.
What happens if standard treatments for Antisynthetase Syndrome do not work?
If first-line medications are not enough, your doctor may recommend advanced therapies like Rituximab. This biologic medication targets the specific immune cells producing harmful autoantibodies and is often used for severe lung involvement.
How is rapidly progressive lung inflammation in ASyS treated?
Rapidly progressive lung disease is a medical emergency that often requires triple therapy. This aggressive approach involves using high-dose steroids, a steroid-sparing agent, and a biologic like Rituximab all at once to quickly halt the lung inflammation.
Can I treat Antisynthetase Syndrome with just prednisone?
Relying only on prednisone without a second medication is generally considered insufficient for ASyS. Long-term use of high-dose steroids causes significant side effects, so adding a steroid-sparing agent is the standard of care to safely control the disease long-term.
Which specialists should be managing my ASyS treatment?
Your care should be closely coordinated between a rheumatologist, who manages the autoimmune disease, and a pulmonologist, who monitors and treats any lung involvement. Lack of communication between these specialists is a red flag in ASyS management.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific goal of our initial treatment—are we looking for complete remission, or is stabilization of my lung function the primary focus?
  2. 2.Why are we choosing Mycophenolate Mofetil (MMF) over Azathioprine (or vice versa) for my specific case?
  3. 3.If my lung function doesn't improve within 3-6 months, what is the 'Plan B' (e.g., Rituximab or a JAK inhibitor)?
  4. 4.How will we know when it is safe to start 'tapering' (reducing) my prednisone dose?
  5. 5.What are the specific side effects I should watch for with my immunosuppressant, and how will we monitor my liver and blood counts?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    [Clinical and radiological features of adult patients with different antisynthetase syndrome based on serum anti-aminoacyl-tRNA synthetase antibody type].

    Li S, Huang H, Song XY, et al.

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2017; (40(12)):919-924 doi:10.3760/cma.j.issn.1001-0939.2017.12.011.

    PMID: 29224302
  2. 2

    Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab.

    Rüegg CA, Maurer B, Laube I, Scholtze D

    BMJ case reports 2019; (12(9)) doi:10.1136/bcr-2019-231006.

    PMID: 31519721
  3. 3

    A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.

    Patel P, Marinock JM, Ajmeri A, Brent LH

    International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084453.

    PMID: 38674039
  4. 4

    A multidisciplinary approach to the diagnosis of antisynthetase syndrome.

    Wells M, Alawi S, Thin KYM, et al.

    Frontiers in medicine 2022; (9()):959653 doi:10.3389/fmed.2022.959653.

    PMID: 36186825
  5. 5

    Acute Respiratory Distress Syndrome as the Initial Clinical Manifestation of an Antisynthetase Syndrome.

    Kim SH, Park IN

    Tuberculosis and respiratory diseases 2016; (79(3)):188-92 doi:10.4046/trd.2016.79.3.188.

    PMID: 27433180
  6. 6

    Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort.

    Sharma N, Putman MS, Vij R, et al.

    The Journal of rheumatology 2017; (44(11)):1612-1618 doi:10.3899/jrheum.161217.

    PMID: 28864644
  7. 7

    Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?

    Bautista-Sanchez R, Khanna D

    Rheumatology and immunology research 2024; (5(3)):157-165 doi:10.2478/rir-2024-0022.

    PMID: 39439972
  8. 8

    MMF Is an Effective and Safer Treatment Options for Treatment-Naïve Patients With Autoimmune Hepatitis Compared to Azathioprine: A Systematic Review and Meta-Analysis.

    Anwar MT, Shahzil M, Arif TB, et al.

    Journal of digestive diseases 2025; (26(3-4)):113-128 doi:10.1111/1751-2980.13348.

    PMID: 40386905
  9. 9

    Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases.

    Mostkowska A, Rousseau G, Raynal NJ

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2024; (38(5)):e23536 doi:10.1096/fj.202302259RR.

    PMID: 38470360
  10. 10

    Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study.

    Sun S, Jin J, Chen J, et al.

    Seminars in arthritis and rheumatism 2025; (72()):152712 doi:10.1016/j.semarthrit.2025.152712.

    PMID: 40122014
  11. 11

    Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease.

    Vacchi C, Manfredi A, Cassone G, et al.

    Drugs in context 2021; (10()) doi:10.7573/dic.2020-8-7.

    PMID: 33505478
  12. 12

    A Rare Case Report of Antisynthetase Syndrome With Progressive Myopathy and Interstitial Lung Disease in a 38-Year-Old Male.

    Ali M, Tariq MU, Hassan M, et al.

    Clinical case reports 2026; (14(2)):e72059 doi:10.1002/ccr3.72059.

    PMID: 41716450
  13. 13

    Rapidly progressive respiratory failure due to antisynthetase syndrome related interstitial lung disease.

    Almubarek M, Boy DP, Lalla U, et al.

    Respirology case reports 2023; (11(5)):e01141 doi:10.1002/rcr2.1141.

    PMID: 37065168
  14. 14

    Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies.

    Yanagihara T, Suzuki K, Egashira A, et al.

    Respiratory medicine case reports 2020; (31()):101272 doi:10.1016/j.rmcr.2020.101272.

    PMID: 33163354
  15. 15

    Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.

    Imai Y, Yorozuya T, Hatakeyama T, et al.

    Journal of medical case reports 2024; (18(1)):471 doi:10.1186/s13256-024-04793-9.

    PMID: 39334485
  16. 16

    One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease-a systemic review and meta-analysis.

    Tangborwornweerakul B, Phutthinart N, Disayabutr S, Katchamart W

    Seminars in arthritis and rheumatism 2024; (69()):152564 doi:10.1016/j.semarthrit.2024.152564.

    PMID: 39423699
  17. 17

    Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review.

    La Rocca G, Ferro F, Baldini C, et al.

    Frontiers in medicine 2023; (10()):1158768 doi:10.3389/fmed.2023.1158768.

    PMID: 36993798
  18. 18

    Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases.

    Baumann Benvenuti F, Dudler J

    RMD open 2023; (9(4)) doi:10.1136/rmdopen-2023-003599.

    PMID: 38097273
  19. 19

    Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.

    Düsing C, Györfi AH, Stütz AN, et al.

    Nature medicine 2026; (32(4)):1530-1542 doi:10.1038/s41591-026-04238-4.

    PMID: 41714747
  20. 20

    Antisynthetase syndrome and interstitial lung disease: A case report.

    Dahal K, Chaudhary A, Rawal L, et al.

    Annals of medicine and surgery (2012) 2022; (82()):104571 doi:10.1016/j.amsu.2022.104571.

    PMID: 36268301
  21. 21

    Interstitial lung disease in rheumatic diseases: an update of the 2018 review.

    Atzeni F, Alciati A, Gozza F, et al.

    Expert review of clinical immunology 2025; (21(2)):209-226 doi:10.1080/1744666X.2024.2407536.

    PMID: 39302018

This page provides educational information about standard treatment pathways for Antisynthetase Syndrome (ASyS). It does not replace professional medical advice; always consult your rheumatologist and pulmonologist for your specific treatment plan.

Get notified when new evidence is published on Antisynthetase syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.